Skip to main content

Idiopathic Nephrotic Syndrome clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

    open to eligible people ages 2-25

    This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).

    San Francisco, California and other locations

Last updated: